Science behind phase I clinical trials: targeting tumour cell development pathways

Comment on progression free survival in lung cancer patients and the GALAXY-1 trial

Crizotinib and molecular testing in advanced non small cell lung cancer

Nintedanib in combination with standard second line therapy in lung cancer

One in five african american women with breast cancer carry inherited mutations

Ipilimumab and BRAF inhibitors for advanced melanoma

Effect of metformin on cancer risk and mortality

Effects of The Cancer Genome Atlas

Improving outcomes of childhood neuroblastoma

Profiles of malignant GCTs and potential biomarkers for CNS germ cell tumours

State of CNS germ cell tumour research in North America

Possible consequences and potential for improvement for time of diagnosis for intracranial germ cell tumours